IDEXX Laboratories, Inc. ( IDXX ) NASDAQ Global Select

Cena: 711.46 ( -0.84% )

Aktualizacja 12-05 21:53
NASDAQ Global Select
Branża: Medycyna - Diagnostyka i badania

Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

symbol 1D 5D 1M 3M 6M YTD 1Y 3Y 5Y 10Y
IDXX -0.5 -3.7 0.1 11.1 36.0 74.7 63.9 71.9 55.5 917.4
Notowania:

Opis firmy:

IDEXX Laboratories, Inc. opracowuje, produkuje i dystrybuuje produkty i usługi przede wszystkim na rynki towarzyszące zwierząt weterynaryjnych, zwierząt gospodarskich i drobiu, nabiału i testowania wody na całym świecie. Firma działa za pośrednictwem CAG; Produkty jakości wody; LPD; i inne segmenty. Zapewnia produkty diagnostyczne weterynaryjne w zakresie opieki, w tym instrumenty, materiały eksploatacyjne i zestawy testowe szybkiego testu; weterynaryjne usługi diagnostyczne i konsultacyjne laboratoryjne; praktyka zarządzania i diagnostyczne systemy i usługi obrazowania dla lekarzy weterynarii; oraz monitorowanie zdrowia, testowanie materiałów biologicznych oraz laboratoryjne instrumenty diagnostyczne zwierząt i usługi dla społeczności badawczej. Firma oferuje również produkty diagnostyczne i monitorujące zdrowie dla zwierząt gospodarskich, drobiu i nabiału; produkty, które testują wodę dla różnych zanieczyszczeń mikrobiologicznych; oraz elektrolity i analizatory gazów krwi oraz SARS-COV-2 RT-PCR, które są stosowane na rynku diagnostyki medycznej ludzkiej opieki; Chemia w klinicznej, chemia krwi i moczu, hematologia i analizy DX uszywczy; Zestawy testowe Snap Szybkie testy. Ponadto zapewnia testy colilert, colilert-18 i kolisury, które wykrywają obecność całkowitej grupy coli i E. coli w wodzie; Enterolelert, Pseudalelert, Filta-Max i Filta-Max Xpress, Legioolert i Quanti Tayt; Oprogramowanie weterynaryjne i usługi dla niezależnych klinik weterynaryjnych i grup korporacyjnych. Firma sprzedaje swoje produkty poprzez marketing, obsługę klienta, sprzedaż i techniczne grupy usług, a także poprzez niezależnych dystrybutorów i innych sprzedawców. Idexx Laboratories, Inc. został włączony w 1983 roku i ma siedzibę w Westbrook, Maine.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medycyna - Diagnostyka i badania
Zatrudnienie: 11 000
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98.975
Ilość akcji: Brak danych
Debiut giełdowy: 1991-06-21
WWW: https://www.idexx.com
CEO: Mr. Jonathan J. Mazelsky
Adres: One IDEXX Drive
Siedziba: 04092 Westbrook
ISIN: US45168D1046
Wskaźniki finansowe
Kapitalizacja (USD) 56 811 426 498
Aktywa: 3 293 443 000
Cena: 711.46
Wskaźnik Altman Z-Score: 24.27
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 57.0
Ilość akcji w obrocie: 99%
Średni wolumen: 517 874
Ilość akcji 79 851 330
Wskaźniki finansowe
Przychody TTM 4 037 710 000
Zobowiązania: 1 698 130 000
Przedział 52 tyg.: 356.14 - 769.98
Piotroski F-Score:
EPS: 12.5
P/E branży: 31.3
Beta: 1.357
Raport okresowy: 2026-02-03
WWW: https://www.idexx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Sharon E. Underberg Executive Vice President, General Counsel, & Corporate Secretary 881 053 1961
Mr. Jonathan J. Mazelsky President, Chief Executive Officer & Director 2 768 770 1961
Mr. Brian P. McKeon Chief Financial Officer, Executive Vice President & Treasurer 1 395 155 1962
Mr. Michael J. Lane Executive Vice President and GM of Reference Laboratories & Information Technology 1 171 099 1969
Mr. John Hart Senior Vice President of Global Operations 0 0
Mr. Jeffery D. Chadbourne Senior Vice President of Commercial Finance & Sales Operations 0 1976
Dr. Martin Smith Ph.D. Executive Vice President & Chief Technology Officer 0 1969
Mr. Ken Grady Senior Vice President & Chief Information Officer 0 0
Mr. George J. Fennell Senior Vice President & Chief Revenue Officer 0 1969
Mr. Michael P. Johnson Executive Vice President & Chief Human Resources Officer 0 1978
Lista ETF z ekspozycją na akcje IDEXX Laboratories, Inc.
Symbol ETF Ilość akcji Wartość
VTI 2 511 296 1 580 885 944
VTS.AX 2 511 296 1 580 885 945
VOO 1 994 486 1 255 548 881
VO 1 760 718 1 108 389 588
QQQ 1 685 274 1 223 357 249
VUG 1 009 653 635 586 660
IVV 998 785 725 028 019
XUU.TO 998 785 3 729 559
XWD.TO 998 785 1 080 919
XSP.TO 998 785 13 850 993
XUS.TO 998 785 10 846 111
IHVV.AX 998 785 3 211 767
IVV.AX 998 785 13 224 181
XAW.TO 998 785 2 086 814
SPY 965 901 663 693 090
VOT 687 885 433 030 486
XLV 566 112 391 236 153
IWP 538 723 391 064 412
IWF 315 788 229 233 667
IWR 293 146 212 797 612
QQQM 289 895 210 437 679
IHI 289 135 209 885 987
QUAL 254 459 184 714 332
XQLT.TO 254 459 768 433
GSPX.L 248 699 137 746 503
VHT 242 163 152 444 030
RSP 226 055 164 095 585
CBUC.DE 203 234 127 952 526
CSSPX.MI 189 757 119 467 542
SXR8.DE 189 757 119 467 542
CSPX.AS 189 757 119 467 542
CSP1.L 189 757 105 100 582
CSPX.L 189 757 137 746 503
EEDS.L 176 265 127 952 526
EEDG.L 176 265 97 627 777
OM3L.DE 176 265 110 973 225
EDMU.SW 176 265 127 952 526
EDMU.DE 176 265 110 973 225
IWDG.L 165 841 91 854 473
FIW 163 332 88 854 287
SPHQ 157 045 114 000 535
SCHG 147 165 102 113 124
IWLE.DE 145 898 91 854 473
IVE 142 644 103 546 706
U127.L 134 872 90 624 126
LEMA.L 134 872 90 624 126
E127.L 134 872 69 145 082
SPYM 133 066 91 641 905
SPLG 130 493 82 406 854
IWDA.L 126 537 91 854 473
SWDA.MI 126 537 79 665 385
IWDD.AS 126 537 91 854 473
IWDA.AS 126 537 79 665 385
SWDA.L 126 537 70 084 963
EUNL.DE 126 537 79 665 385
NQSE.DE 114 445 72 052 374
VUAA.DE 108 538 59 258 928
VUAG.L 108 538 52 132 552
VUSA.MI 108 538 59 258 928
VUSA.L 108 538 52 132 552
VUSA.DE 108 538 59 258 928
VUAA.MI 108 538 59 258 928
VUSD.L 108 538 68 325 756
VUSA.AS 108 538 59 258 928
VUAA.L 108 538 68 325 756
VONG 108 416 68 248 956
SXRV.DE 99 258 62 491 024
CNDX.L 99 258 72 052 374
CSNDX.SW 99 258 72 052 374
CNX1.L 99 258 54 975 961
GSLC 99 099 53 576 883
ITOT 96 695 70 191 867
XEQT.TO 96 695 4 496 419
XCNS.TO 96 695 48 734
XINC.TO 96 695 7 848
XGRO.TO 96 695 1 287 358
XBAL.TO 96 695 623 632
VV 94 083 59 226 189
SPYV 94 049 64 679 252
DUHP 87 824 60 541 474
SCHX 80 602 56 122 618
IUSV 68 233 49 531 017
TQQQ 65 086 47 246 578
IWB 58 978 42 812 719
VT 57 543 36 223 893
ESGU 56 381 40 927 531
DFAC 55 845 38 496 750
SGWS.L 53 878 29 841 434
SCWS.SW 50 879 29 841 434
IYH 48 143 34 947 485
QGRO 47 544 32 774 456
2B7K.DE 47 399 29 841 434
SUSW.L 47 399 29 841 434
SCHB 46 086 32 120 625
IUHE.AS 45 608 28 714 095
XHC.TO 44 996 4 142 684
IXJ 44 996 32 663 046
IXJ.AX 44 996 10 951 349
IMCG 42 964 31 187 997
VWRP.L 42 722 20 520 065
VWRL.AS 42 722 23 325 102
VWRL.L 42 722 20 520 065
VWRD.L 42 722 26 893 926
VWRA.L 42 722 26 893 926
VGWL.DE 42 722 23 325 102
VWCE.DE 42 722 23 325 102
SUWU.SW 41 762 27 036 820
SUWS.L 41 109 29 841 434
2B7J.DE 41 109 25 881 475
SUWG.L 41 109 22 769 014
JQUA 40 660 29 515 500
IUHC.L 39 556 28 714 095
IHCU.L 39 556 21 908 855
QDVG.DE 39 556 24 903 735
QQXT 37 508 4 833 834
USAC.PA 36 841 22 199 521
LYYB.DE 36 841 22 199 521
USA.PA 36 841 22 199 521
SUSA 35 116 25 491 055
QQEW 34 833 20 488 809
EMND.DE 34 307 21 599 060
EEWG.L 34 307 19 001 595
EDMW.DE 34 307 21 599 060
EEWD.L 34 307 24 903 794
EGMW.L 34 307 19 001 595
FHLC 34 281 21 701 587
QYLD 34 117 22 865 554
QLD 33 126 24 046 494
VGS.AX 33 010 31 742 343
AVUS 30 535 21 049 302
SAUA.MI 29 837 18 785 098
NULG 29 835 13 833 296
PWB 29 610 21 494 195
PABU 29 361 21 313 443
SUAP.L 28 781 15 940 983
IUSA.DE 27 858 17 538 888
IUSA.L 27 858 15 429 691
IUSA.AS 27 858 17 538 888
IDUS.L 27 858 20 222 400
QQQI 27 018 19 612 636
GPSA.L 25 878 14 333 030
SLUS.DE 25 878 16 292 316
SASU.L 25 878 18 785 098
SDUS.L 25 878 18 785 098
SGAS.DE 25 878 16 292 316
3SUR.DE 25 320 15 940 983
EXXT.DE 23 794 14 980 267
XAMB.DE 23 420 14 178 312
WESE.PA 23 420 14 178 312
MWSH.DE 23 420 14 178 312
DFUS 22 726 15 666 168
IWV 22 526 16 351 848
IUSQ.DE 22 187 13 968 530
ISAC.L 22 187 16 105 765
SSAC.L 22 187 12 288 698
FXH 22 185 13 416 994
SUUS.L 21 960 12 162 970
SUAS.L 21 960 15 940 983
SRIL.AS 21 960 15 940 983
QDVR.DE 21 960 13 825 615
36B6.DE 21 960 13 825 615
QUAL.AX 20 894 22 529 317
ACWI 20 778 15 082 957
ONEQ 19 361 12 256 481
VOOV 18 402 11 584 243
AHYQ.DE 17 963 10 831 752
RSPH 17 900 12 993 789
ESGV 17 649 11 110 221
QQQE 17 594 12 128 423
LYTR.DE 16 872 10 057 410
C099.DE 16 872 10 057 410
I500.L 16 378 0
I50D.AS 16 378 0
I500.AS 16 378 0
WHCA.AS 15 933 10 031 125
WHCS.AS 15 933 11 565 924
CBUF.DE 15 933 10 031 125
ISPE.L 15 857 8 782 785
MWRD.MI 14 993 9 054 454
SPTM 14 531 10 016 974
DFAU 14 370 9 905 959
QGRW 13 850 10 053 853
IWFQ.L 13 831 7 660 566
IWQU.L 13 831 10 040 061
IS3Q.DE 13 831 8 707 745
KNOW 13 117 0
PBUS 12 904 9 367 142
VONE 12 834 8 079 131
DSI 12 725 9 237 204
XQQ.TO 12 426 12 741 423
SP5C.PA 12 353 7 474 878
SP5C.L 12 353 8 615 843
6TVM.DE 12 353 7 474 878
SP5G.L 12 353 6 573 781
LSPX.L 12 353 657 378 151
SP5L.L 12 353 6 573 781
LYSPH.SW 12 353 6 960 980
SP5H.PA 12 353 7 474 878
LSPU.L 12 353 8 615 843
LYP2.DE 12 353 7 474 878
SPHC.MI 12 353 7 474 878
LYPS.DE 12 353 7 474 878
ETFSP500.WA 12 353 31 668 442
IBCF.DE 12 230 7 699 953
IUSE.L 12 230 7 699 953
EWSP.L 12 099 6 701 265
FNDX 12 074 8 463 329
FQAL 11 652 7 376 298
FTC 11 597 7 450 740
UMDV.AS 11 145 8 090 266
IMCB 9 276 6 733 541
VGVE.DE 9 168 5 005 489
VHVG.L 9 168 4 403 538
VDEV.L 9 168 5 771 347
VGVF.DE 9 168 5 005 489
VEVE.L 9 168 4 403 538
VHVE.L 9 168 5 771 347
LWCR.DE 8 912 5 360 044
LWCR.PA 8 912 5 360 044
ANXG.L 8 815 469 191 407
ANX.PA 8 815 5 335 054
6AQQ.DE 8 815 5 335 054
HNDX.DE 8 815 5 335 054
ANXU.L 8 815 6 149 397
BBUS 8 781 6 374 215
IDWR.L 8 306 6 029 408
IWRD.L 8 306 4 600 438
IQQW.DE 8 306 5 229 305
IWRD.AS 8 306 5 229 305
QDVB.DE 8 214 5 171 384
IUQD.L 8 214 5 962 624
IUQA.L 8 214 5 962 624
IUQF.L 8 214 4 549 482
BIBL 7 903 5 736 866
ILCG 7 714 5 599 669
OMFL 7 620 5 531 434
IS31.DE 7 431 4 678 489
USCA 7 120 5 168 479
SSO 6 983 5 069 029
PAWZ 6 937 5 035 637
SDWD.L 6 793 4 931 106
SAWD.L 6 793 4 931 106
SNAW.DE 6 793 4 276 748
S6DW.DE 6 793 4 276 748
VNRT.DE 6 625 3 617 077
VNRG.L 6 625 3 182 094
VNRA.L 6 625 4 170 503
VNRT.L 6 625 3 182 094
VDNR.L 6 625 4 170 503
VNRA.DE 6 625 3 617 077
FEX 6 498 4 123 894
URTH 6 485 4 707 526
SPMV.L 6 445 4 678 489
SPMD.L 6 445 4 678 489
MVUS.L 6 445 3 569 687
IBCK.DE 6 445 4 057 654
VTHR 6 273 3 948 916
QFLR 6 195 4 497 012
SCHK 6 062 4 222 084
500.PA 6 054 3 663 525
500U.L 6 054 4 222 725
H1D5.DE 6 054 3 663 525
AUM5.DE 6 054 3 663 525
QHAL.AX 5 792 6 245 046
USCL 5 700 4 137 687
SPXL 5 672 3 909 993
AASU.L 5 582 3 738 610
AMEA.DE 5 582 3 243 519
AASI.PA 5 582 3 243 519
AASG.L 5 582 285 251 339
AASU.SW 5 582 3 738 610
100H.PA 5 421 3 250 782
100H.L 5 421 3 746 981
100D.L 5 421 285 890 027
L100.L 5 421 285 890 027
PTNQ 5 375 3 901 766
IBCH.DE 5 145 3 239 029
IWDE.L 5 145 3 239 029
BCHP 5 133 3 538 433
GPIQ 5 088 2 750 776
GSEW 4 758 2 572 365
PTLC 4 676 3 394 355
AVLV 4 633 3 193 758
NRAM.PA 4 633 2 811 761
AVMV 4 476 3 085 530
SPUS 4 473 3 246 995
USXF 4 398 3 192 552
CU1.L 4 077 2 258 125
SXR4.DE 4 077 2 566 804
CSUS.SW 4 077 2 959 535
CSUS.L 4 077 2 959 535
XYLD 4 038 2 706 307
CATH 3 975 2 664 084
EUSA 3 883 2 818 708
VFQY 3 750 2 395 837
VGAD.AX 3 739 3 595 869
XHE 3 708 2 595 393
PRF 3 526 2 559 558
SPYX 3 488 2 404 452
RISN 3 444 2 500 034
IYY 3 429 2 489 145
QUS 3 356 2 182 465
UPRO 3 340 2 424 539
PABW.DE 3 295 1 983 964
PABW.PA 3 295 1 983 964
DFSU 3 102 2 138 363
PTL 3 053 2 216 203
JOET 3 034 2 202 410
GUSA 2 715 1 467 837
SUSL 2 577 1 870 670
ROUS 2 466 1 699 937
DCOR 2 462 1 697 179
RWL 2 412 1 750 894
ESGI.AX 2 377 2 563 041
QVML 2 333 1 693 548
JHML 2 263 1 577 537
TOLL 2 251 1 634 023
FINW.L 2 232 1 551 055
LYPD.DE 2 232 1 345 654
PALC 2 193 1 591 920
TMFC 2 189 0
HLAL 2 170 1 495 889
CURE 2 144 1 477 966
INR.PA 2 030 1 198 420
LYINR.SW 2 030 1 381 347
INRL.L 2 030 105 395 070
INRU.L 2 030 1 381 347
LYMD.DE 2 030 1 198 420
CM9.PA 1 947 1 175 711
IGUS.L 1 939 1 073 942
AVLC 1 915 1 320 105
IWLD.AX 1 862 2 100 620
IWDC.SW 1 815 1 064 830
NUSI 1 812 784 596
IUSZ.L 1 770 1 284 860
IUSF.L 1 770 980 348
QDVC.DE 1 770 1 114 359
LSAF 1 768 1 283 408
INAA.L 1 752 970 379
IDNA.L 1 752 1 271 794
INAA.SW 1 752 1 271 794
IQQN.DE 1 752 1 103 027
QLC 1 745 1 266 712
MID 1 706 1 089 946
PE500.PA 1 675 1 015 821
P500H.PA 1 675 1 015 821
TILT 1 672 1 213 721
QDPL 1 661 1 205 736
LESU.DE 1 636 1 029 089
GPIX 1 617 874 214
XSUS.TO 1 607 1 647 792
ILCB 1 581 1 147 663
CSM 1 566 1 136 775
DFVX 1 523 1 049 880
ISPY 1 489 1 080 879
CRBN 1 464 1 062 732
FAD 1 436 1 076 524
QQA 1 428 1 036 599
AVSU 1 416 976 119
IUSC.SW 1 355 795 394
V3AM.L 1 347 646 985
V3AL.L 1 347 847 949
V3AB.L 1 347 646 985
V3AA.L 1 347 847 949
STRV 1 323 922 263
USSG 1 291 937 149
VOTE 1 275 878 921
R1GR.L 1 267 919 727
IQQQ 1 244 903 032
SIZE 1 242 901 580
MODL 1 224 888 513
NTSX 1 191 864 558
RSPA 1 153 836 974
IHWL.AX 1 153 1 300 760
SPYI 1 148 833 344
IWQE.MI 1 120 705 131
VESG.AX 1 094 1 051 540
CFA 1 086 788 338
ETHO 1 041 755 672
XUSR.TO 1 021 1 046 917
GDE 984 714 295
GGUS 962 520 095
EQAL 937 680 177
EPS 895 649 689
IS3T.DE 865 544 588
IWSZ.L 865 627 912
IWFS.L 865 479 096
CFO 848 615 571
JMID 842 611 216
RXL 837 607 586
WPAB.AS 832 603 957
WPAD.AS 832 603 957
WPAB.SW 824 533 187
IQSU 804 0
USNZ 804 583 631
KOKU 778 564 757
QQMG 749 543 706
XVV 736 534 269
BFOR 702 509 588
OALC 692 455 377
AVMC 690 475 651
HCMT 622 428 775
WEBA.DE 611 314 567
XUH.TO 544 395 106
FNDB 538 378 346
DXUV 534 368 112
MEDI 529 364 666
QYLG 522 349 849
IGWD.L 503 278 470
SPXT 503 365 132
BLES 488 354 244
CRTC 487 353 518
SAWI.AS 451 327 385
CBUY.DE 451 283 941
PBP 443 321 578
MFUS 431 312 867
IUS 391 283 830
AFLG 391 577 098
DEUS 371 269 312
MMTM 345 237 820
DUBS 317 230 113
QQQG 309 224 306
QNXT 303 219 950
LSEQ 294 202 668
ACWL.L 278 14 687 867
ACWU.L 278 192 504
ACWI.PA 278 167 011
LYY0.DE 278 167 011
HQGO 277 190 949
STXG 274 191 005
EGV2.DE 265 160 821
SMTC.L 265 185 368
CSH2.PA 265 160 821
CSH2.L 265 14 143 411
SPUU 262 180 609
QWLD 262 173 522
VLU 262 179 248
TOK 242 175 670
NZAC 237 163 380
EGUS 235 170 588
ESG 224 162 603
GEQT.TO 222 227 339
GLOF 200 145 182
GGRO.TO 200 204 715
ONOF 192 128 680
ONEO 182 125 465
GBAL.TO 141 144 862
QARP 124 90 012
XMAG 122 88 561
VMO.TO 116 103 118
SPXN 111 80 576
SPXE 105 76 220
NVIR 105 76 221
SPGM 100 68 933
HDUS 97 66 866
XYLG 85 56 967
IUME.AS 83 53 960
PHDG 73 52 991
QRMI 71 47 584
XRMI 61 40 882
NULC 51 23 646
WLDX.MI 38 23 088
NTSX.L 30 21 777
NTSX.MI 30 21 777
GCNS.TO 30 31 204
WDMF.AX 27 30 460
JCTR 18 11 361
QHDG 16 11 614
QCLR 15 10 053
SPMV 14 10 162
QTR 13 8 712
NZUS 12 8 276
INRO 9 6 533
XCLR 5 3 351
XTR 3 2 010
SPES.L 0 0
SPXD.L 0 0
ESGU.L 0 0
EQSG.L 0 0
FWRG.L 0 0
P500.DE 0 0
G500.L 0 0
EQCH.SW 0 0
EQGB.L 0 0
EQQQ.MI 0 0
FWRA.MI 0 0
ESGW.DE 0 0
PSRF.L 0 0
IGDA.L 0 0
NESG.L 0 0
SPXS.L 0 0
SPXP.L 0 0
ESGS.L 0 0
ESGG.L 0 0
XLVS.L 0 0
IQSA.DE 0 0
FWRA.SW 0 0
EQL.TO 0 2 987 981
D500.DE 0 0
PRUS.L 0 0
ESPB.L 0 0
EQAC.SW 0 0
MXUS.L 0 0
SPEX.L 0 0
MXWO.L 0 0
SPXS.MI 0 0
6PSA.DE 0 0
SPED.L 0 0
SC0J.DE 0 0
EQQU.L 0 0
FTWD.DE 0 0
IQSA.L 0 0
FTWG.L 0 0
PXS.TO 0 11 436
EQQQ.DE 0 0
EQQQ.L 0 0
PAUS.L 0 0
ESGW.L 0 0
E500.DE 0 0
EQQD.L 0 0
FCTR 0 251 164
IQSE.DE 0 0
XLVP.L 0 0
QQC.TO 0 3 929 346
SC0H.DE 0 0
EQEU.DE 0 0
EQQS.L 0 0
MXWS.L 0 0
SPXD.SW 0 0
QQC-F.TO 0 3 743 110
MXUD.L 0 0
SPEQ.L 0 0
ESGU.DE 0 0
Wiadomości dla IDEXX Laboratories, Inc.
Tytuł Treść Źródło Aktualizacja Link
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. zacks.com 2025-05-15 13:11:13 Czytaj oryginał (ang.)
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion. seekingalpha.com 2025-05-14 18:35:10 Czytaj oryginał (ang.)
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year? Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year. zacks.com 2025-05-14 14:41:31 Czytaj oryginał (ang.)
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on. businesswire.com 2025-05-13 18:30:00 Czytaj oryginał (ang.)
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-05-01 14:36:17 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2025-05-01 14:35:25 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago. zacks.com 2025-05-01 12:40:23 Czytaj oryginał (ang.)
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increased demand for its tests and equipment. reuters.com 2025-05-01 12:21:46 Czytaj oryginał (ang.)
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories,” said Jay Mazelsky, President and Chief Executive Officer. “Customers have been askin. businesswire.com 2025-05-01 10:30:00 Czytaj oryginał (ang.)
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar. zacks.com 2025-04-30 14:35:40 Czytaj oryginał (ang.)
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-29 14:50:57 Czytaj oryginał (ang.)
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025. zacks.com 2025-04-29 14:21:11 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-24 15:08:53 Czytaj oryginał (ang.)
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock? IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities. zacks.com 2025-04-21 13:35:41 Czytaj oryginał (ang.)
IDEXX (IDXX) Surges 10.0%: Is This an Indication of Further Gains? IDEXX (IDXX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com 2025-04-10 10:50:37 Czytaj oryginał (ang.)
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-04-09 14:45:33 Czytaj oryginał (ang.)
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-04 17:15:45 Czytaj oryginał (ang.)
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com 2025-04-04 13:55:40 Czytaj oryginał (ang.)
IDEXX Laboratories to Release 2025 First Quarter Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website,. businesswire.com 2025-04-03 17:30:00 Czytaj oryginał (ang.)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. zacks.com 2025-04-02 13:55:56 Czytaj oryginał (ang.)
Should You Hold IDEXX Stock in Your Portfolio for Now? IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising. zacks.com 2025-02-18 10:50:25 Czytaj oryginał (ang.)
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March. businesswire.com 2025-02-13 16:00:00 Czytaj oryginał (ang.)
IDEXX Laboratories And Its Real Value IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years. seekingalpha.com 2025-02-10 13:27:02 Czytaj oryginał (ang.)
Why Idexx Labs Stock Rocketed Higher This Week Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. fool.com 2025-02-07 09:09:14 Czytaj oryginał (ang.)
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage. seekingalpha.com 2025-02-06 16:31:03 Czytaj oryginał (ang.)
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers. Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street. barrons.com 2025-02-03 13:31:00 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2025-02-03 13:26:14 Czytaj oryginał (ang.)
IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices. investopedia.com 2025-02-03 13:22:29 Czytaj oryginał (ang.)
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-02-03 12:30:42 Czytaj oryginał (ang.)
Idexx: Q4 EPS, Revenue Beat Forecast Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million. fool.com 2025-02-03 11:06:09 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago. zacks.com 2025-02-03 10:41:23 Czytaj oryginał (ang.)
Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to the vet clinic. reuters.com 2025-02-03 09:57:11 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. “IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally,” said Jay Mazelsky, President and Chief Executive Officer. "The Company is on the front end of a new wave of major innovation. In Q4, we began shipping the IDEXX inVue Dx™ Cellular Analyzer, our transformational sli. businesswire.com 2025-02-03 08:30:00 Czytaj oryginał (ang.)
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock? IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities. zacks.com 2025-01-27 12:11:14 Czytaj oryginał (ang.)
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma. zacks.com 2025-01-24 11:01:16 Czytaj oryginał (ang.)
IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2024 Earnings Snapshot through a link on. businesswire.com 2025-01-16 18:15:00 Czytaj oryginał (ang.)
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check. zacks.com 2025-01-15 12:41:32 Czytaj oryginał (ang.)
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-26 12:46:11 Czytaj oryginał (ang.)
SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX Sustainability Roundtable Inc. announced Synopsys, IDEXX, and Juniper Networks as winners of the 2024 SBER Awards for standout leadership in sustainability globenewswire.com 2024-12-19 12:09:00 Czytaj oryginał (ang.)
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025 One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities. fool.com 2024-12-13 10:45:00 Czytaj oryginał (ang.)
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. zacks.com 2024-12-11 14:01:21 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. Thes. businesswire.com 2024-12-09 09:30:00 Czytaj oryginał (ang.)
Should You Hold IDEXX Stock in Your Portfolio for Now? IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising. zacks.com 2024-11-22 13:15:19 Czytaj oryginał (ang.)
IDEXX Announces CFO Transition WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX's Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Co. businesswire.com 2024-11-21 09:30:00 Czytaj oryginał (ang.)
IDEXX Laboratories Q3: Weak End-Market Demand Continues I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. seekingalpha.com 2024-11-10 21:50:02 Czytaj oryginał (ang.)
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. fool.com 2024-11-06 06:11:00 Czytaj oryginał (ang.)
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today. fool.com 2024-11-05 11:53:00 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2024-10-31 15:59:07 Czytaj oryginał (ang.)
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points inclu. businesswire.com 2024-10-31 15:15:00 Czytaj oryginał (ang.)
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68. benzinga.com 2024-10-31 14:55:09 Czytaj oryginał (ang.)
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments. zacks.com 2024-10-31 14:10:27 Czytaj oryginał (ang.)
Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-10-31 12:36:22 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago. zacks.com 2024-10-31 10:40:21 Czytaj oryginał (ang.)
IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners. reuters.com 2024-10-31 10:01:34 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company reports revenues of $976 million for the third quarter of 2024, an increase of 7% as reported and 6% organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and 6% organic, and Water revenue growth of 13% as reported and organic. CAG Diagnostics recurring revenue growth of 7% as repor. businesswire.com 2024-10-31 08:30:00 Czytaj oryginał (ang.)
Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com 2024-10-28 12:21:45 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy? Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-24 15:05:37 Czytaj oryginał (ang.)